Table of Contents
Chapter 1. Human Drug Off-label Veterinary Use in U.S. Estimates, by Application (2024)
1.1. Sedation/Analgesia
1.1.1. Key Parameters Covered (for each drug mentioned below) -
1.1.1.1. Drug Name
1.1.1.2. Strength
1.1.1.3. Vial Volume
1.1.1.4. Estimated Revenue 2024 (USD Million)
1.1.1.5. Estimated Sale Volume 2024 (Units)
1.1.2. Key Drugs Covered -
1.1.2.1. Buprenorphine
1.1.2.2. Diazepam
1.1.2.3. Propofol
1.1.2.4. Butorphanol
1.1.2.5. Dexmedetomidine
1.1.2.6. Fentanyl
1.1.2.7. Hydromorphone
1.1.2.8. Methadone
1.2. Oncology
1.2.1. Key Parameters Covered (for each drug mentioned below) -
1.2.1.1. Drug Name
1.2.1.2. Strength
1.2.1.3. Vial Volume
1.2.1.4. Estimated Revenue 2024 (USD Million)
1.2.1.5. Estimated Sale Volume 2024 (Units)
1.2.2. Key Drugs Covered -
1.2.2.1. Carboplatin
1.2.2.2. Doxorubicin
1.2.2.3. Vinblastine
1.2.2.4. Vincristine
1.2.2.5. Chlorambucil
1.2.2.6. Cyclophosphamide
1.2.2.7. Lomustine
Chapter 2. Industry Outlook
2.1. Market Driver Analysis
2.2. Market Restraint Analysis
2.3. Market Opportunity Analysis
2.4. Market Challenge Analysis
2.5. Regulatory Landscape
2.6. Business Activities
2.6.1. Product Launch
2.6.2. Mergers & Acquisitions
2.6.3. Partnerships & Collaborations
2.6.4. Expansion
2.6.5. Others (recognition, product recall, etc.)